Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOY 62 EV-to-FCF is 79.74 as of Aug. 19, 2026, which is 172% above its 10-year median of 29.34. GuruFocus rates KYKOY with a GF Score™ of 62/100 and a GF Value™ of $13.97 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 559 Drug Manufacturers companies, Kyowa Kirin Co ranks worse than 84.26% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kyowa Kirin Co's Enterprise Value is $7,178 Mil.
Kyowa Kirin Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $90 Mil. Therefore, Kyowa Kirin Co's EV-to-FCF for today is 79.74.
The historical rank and industry rank for Kyowa Kirin Co's EV-to-FCF or its related term are showing as below:
KYKOY'
s EV-to-FCF Range Over the Past 10 Years
Min: -37.29 Med: 29.34 Max: 345.2
Current: 79.74
During the past 13 years, the highest EV-to-FCF of Kyowa Kirin Co was 345.20. The lowest was -37.29. And the median was 29.34.
KYKOY's EV-to-FCF is ranked worse than 84.26% of 559
companies
in the Drug Manufacturers industry
Industry Median: 21.39
vs KYKOY: 79.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kyowa Kirin Co (OTCPK:KYKOY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kyowa Kirin Co's PE Ratio (TTM) for today is calculated as:
Kyowa Kirin Co's share price for today is $16.90.
Kyowa Kirin Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.911.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kyowa Kirin Co EV-to-FCF Related Terms
Kyowa Kirin Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's EV-to-FCF falls into.
Kyowa Kirin Co's current Enterprise Value is $7,178 Mil.
Kyowa Kirin Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOY) has a EV-to-FCF of 79.74 as of Aug. 19, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kyowa Kirin Co and its competitors. This is 172% above median its historical median of 29.34. According to the industry distribution chart, Kyowa Kirin Co ranks #471 out of 559 companies in the Drug Manufacturers industry, placing it in the top 84.3%.
Is Kyowa Kirin Co's EV-to-FCF too high?
Kyowa Kirin Co's current EV-to-FCF of 79.74 is 172% above median its 10-year median of 29.34. The Drug Manufacturers industry median EV-to-FCF is 21.39. Kyowa Kirin Co's value of 79.74 is 272.8% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #471 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #471 out of 559 companies for EV-to-FCF. This places Kyowa Kirin Co in the lower half of its industry. The industry median EV-to-FCF is 21.39. Kyowa Kirin Co's value of 79.74 is 272.8% above this benchmark. While the company's 10-year median is 29.34 vs. the industry median of 21.39, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.39, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current EV-to-FCF of 79.74 is 272.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current EV-to-FCF is 79.74, which is 172% above median its own 10-year median of 29.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOY) is currently considered Modestly Overvalued. The stock's GF Value™ is $13.97, compared to a current price of $16.90 — trading 21% above its estimated fair value. The current EV-to-FCF is 79.74, which is 172% above median its 10-year median of 29.34 and 272.8% above the Drug Manufacturers industry median of 21.39. Kyowa Kirin Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOY), the current EV-to-FCF is 79.74 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOY) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be overvalued.
The current stock price of $16.90 is trading 21% above its estimated GF Value™ of $13.97.
GuruFocus considers Kyowa Kirin Co to be Modestly Overvalued.
Key valuation signals for KYKOY:
EV-to-FCF: 79.74 (172% above median its 10-year median of 29.34)
GF Value™: $13.97 vs. price of $16.90 (21% above fair value)
Industry Position: 272.8% above the Drug Manufacturers median (#471 of 559)
No single metric tells the full story. See the KYKOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
62GF Score
Get the complete analysis for KYKOY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOY has been successfully added to your 
